



Council of the
European Union

Brussels, 6 June 2016
(OR. en)

9829/16

JAI 526
CORDROGUE 30
SAN 238

OUTCOME OF PROCEEDINGS

From: General Secretariat of the Council
On: 11 May 2016
To: Delegations
Subject: Outcomes of the Horizontal Working Party on Drugs

1. Adoption of the agenda

The meeting approved the agenda outlined in doc. CM 2513/16 with the addition of the following point under AOB: Request for risk assessment on new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA).

2. Information from the Presidency on:

- the high level meeting on HIV/AIDS in New York in June 2016

The Presidency informed delegations about the above-mentioned meeting and the representative of the UNODC gave an overview of the implementation of the UNAIDS Fast-Track Strategy (2016 – 2021) for people who use drugs and in prisons, which called for a 75% reduction of new HIV infections among key populations, including people who use drugs and people in prisons, by 2020. She also presented the UNODC HIV Work Plan (2016 – 2021) focusing on increased coverage of and access to the comprehensive package of harm reduction interventions for HIV prevention, treatment and care, including in prisons. The speaker explained that out of 12.2 million people injecting drugs, 13.5% lived with HIV and that HIV epidemics was emerging among people injecting new psychoactive substances, and stressed that high coverage of harm reduction measures could substantially decrease new HIV infections. She also elaborated on how the provisions included in the UNGASS Outcome Document contributed to reducing HIV.

- the EU drug market report presentation in COSI Support Group meeting

The Presidency informed the meeting that the above-mentioned report was presented at the COSI Support Group meeting on 14 April 2016.

3. Discussion on the draft legislation on new psychoactive substances

Following COREPER's endorsement of the change of the legal basis to Article 83 TFEU on 6 April 2016 and agreement that the provisions containing information exchange and risk assessment should be hosted under the revised EMCDDA Regulation, the Presidency provided a revised draft NPS Directive. Delegations discussed the new proposal, especially as regards the definition of new psychoactive substances and the period necessary for implementation of national control measures.

4. Misuse of and dependence from prescribed medicines – information by the LU delegation on the activities of the informal expert group

The LU Chair of the informal expert group on misuse of and dependence from prescribed medicines reported on the activities of the group in developing the expert definition of the phenomenon and identifying the appropriate indicators to measure the scope of the phenomenon. To this aim a few questionnaires were sent to experts, and the deadline for answering to the second one was set at 20 May 2016. The Chair also noted that the conclusion document would be submitted to the Presidency for further follow-up.

5. Outcomes of UNGASS 2016

The Presidency reported on the outcomes of the UNGASS on Drugs held on 19-21 April 2016 in New York) and put forward a few questions for reflection as regards the process of EU preparation for this event and the roadmap towards the target date of 2019.

New ideas for expanding international cooperation were put forward. Delegations expressed their satisfaction with the EU preparation process for UNGASS and the role played at UNGASS and stressed the important role of coordination. Also, delegations called for an early preparation for the target date of 2019, including the early planning of the EU demarches towards the other countries.

6. Preparations on the World Health Assembly in May 2016

The Presidency gave an overview of the preparation for the World Health Assembly to be held on 23-28 May 2016 as regards drug issues, informing the delegates that EU statements for this meeting would be prepared in Geneva and therefore inviting the HDG delegates to coordinate with their counterparts in Geneva.

7. Preparation for the EU-CELAC High Level meeting

The Presidency updated delegations on the preparations for the above-mentioned meeting to be held on 16-17 June 2016 in the Hague, inviting delegates to contribute to the agenda of the meeting. The ES delegation proposed to present the Iberoamerican Network of Antidrug Prosecutors (*Red Iberoamericana de Fiscales Antidroga*) on the second day of the meeting. Delegations also discussed the draft Hague declaration and proposed further changes to this document. The Presidency also informed the meeting that the draft annual report of the EU-CELAC cooperation would be provided to CELAC delegations for comments.

8. Preparation of the EU-US dialogue on drugs

The Presidency updated delegations on the forthcoming EU-US dialogue on drugs to be held as a videoconference in June 2016.

9. Preparation of the Dublin Group meeting

The FR Presidency updated delegations on the above-mentioned meeting to be held in June 2016, recalling that regional reports on Africa and America would be discussed during the forthcoming Dublin Group meeting, while the regional reports on Asia and Europe would be considered by the end of 2016. The functioning of the Group would also be discussed at the forthcoming meeting, including the US proposal to establish an informal working group. The speaker also informed the meeting that Romania had put forward its candidacy to take over the chairing of the Dublin Group.

10 AOB

- *Request for risk assessment on new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA)*

The representative of the Commission informed the meeting that the Commission had tabled a request for risk assessment on new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA).
